Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus TEGRETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus TEGRETOL.
BRIVIACT vs TEGRETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Voltage-gated sodium channel blocker; stabilizes neuronal membranes and inhibits repetitive firing. Also inhibits glutamate release and enhances GABA activity.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Initial: 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Maintenance: 800-1200 mg/day in 2-4 divided doses. Maximum dose: 1600 mg/day. Extended-release: 200-400 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Single dose: 25–65 hours (mean ~35 h); chronic therapy: 12–17 hours due to autoinduction; clinical context: requires 3–4 weeks to reach steady-state after dose adjustment.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Primarily hepatic metabolism; ~72% excreted in urine (as metabolites, <2% unchanged), ~28% excreted in feces via bile.
Category C
Category C
Anticonvulsant
Anticonvulsant